The Fee Panel has been created to administer the Contingency Fee Fund as provided in the nationwide settlements to resolve Opioids litigation brought by states and political subdivisions with McKesson Corporation, Cardinal Health, Inc., AmerisourceBergen Corporation, Janssen Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Allergan Finance, LLC / Allergan Limited, CVS, Walgreens, Walmart, Kroger.  Below you will find information and links to documents for counsel seeking to apply for attorneys’ fees from the Contingency Fee Fund.

CURRENT DEADLINES:

Contingency Fee Fund Applications for the G8 (Secondary Manufacturer) Settlement are now available in the Rubris Crosslink system.

The Fee Panel has set March 16, 2026 as deadline for submission of applications for awards from the G8 (Secondary Manufacturer) Contingency Fee Fund.

EXHIBIT R

Zydus Settlement Agreement (“Zydus Agreement”)

Sun Pharma Settlement Agreement (“Sun Pharma Agreement”)

Mylan Settlement Agreement (“Mylan Agreement”)

Indivior Settlement Agreement (“Indivior Agreement”)

Hikma Settlement Agreement (“Hikma Agreement”)

Apotex Settlement Agreement (“Apotex Agreement”)

Amneal Settlement Agreement (“Amneal Agreement”)

Alvogen Settlement Agreement (“Alvogen Agreement”)

Kroger Multistate Settlement Agreement (“Kroger Agreement”)

Allergan Public Global Opioid Settlement Agreement (“Allergan Agreement”)

Teva Global Opioid Settlement Agreement (“Teva Agreement”)

CVS Global Opioid Settlement Agreement (“CVS Agreement”)

Walgreens Global Opioid Settlement Agreement (“Walgreens Agreement”)

Walmart Global Opioid Settlement Agreement (“Walmart Agreement”)

Distributors Settlement Agreement (McKesson Corporation, Cardinal Health, Inc.,and AmerisourceBergen Corporation) (“Distributors Agreement”)

Janssen Master Settlement Agreement (“Janssen Agreement”)

ORDERS AND DOCUMENTS

National Distributor-Janssen Eligibility Requirements

Contingency Fee Fund Distribution Procedures

Contact Counsel Disputes

Fee Panel Order No. 48 Regarding Application Deadline for “Group of Eight” (Secondary Manufacturer) Contingency Fee Awards

Fee Panel Order No. 47 Regarding Contingent Fee Fund Credits and Rebates to Kroger, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 45 Regarding Applications Received for Awards from the Kroger Contingency Fee Fund

Fee Panel Order No. 44 Regarding Extending Application Deadline for Kroger Contingency Fee Awards

Fee Panel Order No. 43 Regarding Application Deadline for Kroger Contingency Fee Awards

Fee Panel Order No. 42 Regarding Common Benefit and Contingent Fee Fund Distributions From the Administrative Expense Account

Fee Panel Order No. 40 Regarding Contingent Fee Fund Credits and Rebates to Walmart, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 39 Regarding Adjustments to Walgreen’s Payment Obligations to the Contingency Fee Fund

Fee Panel Order No. 38 Regarding Adjustments to CVS’s Payment Obligations to the Contingency Fee Fund 

Fee Panel Order No. 35 Regarding Credits and Rebates to Allergan, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 34 Regarding Credits and Rebates to Teva, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 33 Regarding Eligibility of Rhode Island Subdivisions for Teva and Allergan Contingency Fee Funds

Fee Panel Order No. 31 Regarding Applications Received for Awards from the Settling Pharmacy Contingency Fee Funds

Fee Panel Order No. 30 Regarding Extending Application Deadline for Settling Pharmacies Contingency Fee Awards

Fee Panel Order No. 29 Regarding Application Deadline for Settling Pharmacies Contingency Fee Awards

Fee Panel Order No. 28 Regarding Applications Received for Awards from the Teva/Allergan Contingency Fee Fund

Fee Panel Order No. 27 Regarding Application Deadline for Teva/Allergan Contingency Fee Awards

Fee Panel Order No. 26 Regarding Back-Stop Funds in the State of Missouri

Fee Panel Order No. 25 Regarding Back-Stop Funds in the State of Michigan

Fee Panel Order No. 24 Regarding New and Supplemental Applications for Fee and Cost Awards

Fee Panel Order No. 22 Regarding Payment Hold to Counsel For Nassau and Suffolk Counties

Fee Panel Order No. 21 Regarding Contingent Fees in Pennsylvania Cases

Fee Panel Order No. 19 Regarding Ohio Attorney Fee Fund Payments to Distributors

Fee Panel Order No. 18 Regarding Rhode Island Attorney Fee Fund Payments to Distributors

Fee Panel Order No. 17 Regarding Back-Stop Funds in the State of Georgia

Fee Panel Order No. 16 Regarding Back-Stop Funds in the State of Kentucky

Fee Panel Order No. 15 Regarding Back-Stop Funds in the State of New Mexico

Fee Panel Order No. 14 Regarding Credits and Rebates to Distributors, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 12 Regarding Sharing of Information With State Attorneys General

Fee Panel Order No. 11 Regarding Credits and Rebates to Janssen, Establishment of an Administrative Expense Account, and a Prudent Reserves Holdback

Fee Panel Order No. 10 Regarding New Fee Application Deadlines

Fee Panel Order No. 9 Regarding Deadline to Cure Deficient Applications for Contingency Fee Fund Awards

Fee Panel Order No. 8 Regarding Fee Application Questions

Fee Panel Order No. 7 Regarding Applications Received for Awards from the Janssen Contingency Fee Fund

Fee Panel Order No. 6 Regarding Applications Received for Awards from the Distributors Contingency Fee Fund

Fee Panel Order No. 4 Regarding Application Deadline for Contingency Fee Awards (Janssen)

Fee Panel Order No. 3 Regarding Application Deadline for Contingency Fee Awards (Distributors)

Fee Panel Order No. 2 Regarding Application Deadline for Contingency Fee Awards

Fee Panel Order No. 1 Regarding Applications For Fee and Cost Awards

ACCESS TO THE CONTINGENT FEE APPLICATION

The Fee Panel has engaged Rubris Inc. to process Contingent Fee Applications for the National Opioids Settlements through its Crosslink system.  In order to obtain access to the Crosslink System, your firm must be named as Contact Counsel on at least one litigating eligible subdivision for contingent fees (see Exhibit G to the National Distributors / Janssen Settlements).  To request access to the secure application system, you must send an email to CrosslinkSupport@rubris.com and provide the law firm, name and email address for each individual requiring access to the application. At least one attorney must be specified as the account administrator for the law firm and should be identified in the request. Please use the following Email subject: Request for Access to Contingent Fee Application.  Applicants must obtain separate access for each Fund application to which they wish to apply.

If you already have Crosslink credentials for the Contingent Fee Application click HERE.

CONTINGENT FEE APPLICATION TRAINING MATERIALS

If you have received Crosslink credentials for the Contingent Fee Application or if your firm is named as Contact Counsel or Fee Interest Counsel in a Contingent Fee application, you may contact CrosslinkSupport@rubris.com to request access to a training webinar on submitting a Contingent Fee Application through the Crosslink system.